User:Fvasconcellos/monoclonalschecklist

From Wikipedia, the free encyclopedia

This is a list compiled from Cat:Monoclonal antibody stubs, meant to assess the verifiability of all articles in the category.

[edit] A

  • Abagovomab YesY multiple studies
  • Adecatumumab YesY multiple studies
  • Afelimomab YesY multiple studies
  • Altumomab YesY one study
  • Ananeuzumab NoN putative USAN
  • Anatumomab mafenatox YesY rINN, in phase II trials
  • Anergrozumab NoN putative USAN
  • Anetumumab NoN putative USAN for zalutumumab
  • Anrulizumab NoN
  • Apolizumab YesY multiple studies
  • Arcitumomab YesY multiple studies
  • Aselizumab YesY rINN, in phase II trials
  • Atlizumab YesY multiple studies
  • Atorolimumab YesY rINN, but no PubMed results
  • Azulizumab NoN

[edit] B

  • Balizumab NoN putative USAN
  • Bapineuzumab YesY USAN, in phase III trials
  • Basiliximab YesY in clinical use
  • Bavituximab YesY one study, in open label trials
  • Bectumomab YesY one study
  • Belizumab NoN putative USAN
  • Bertilimumab YesY rINN, in phase II trials
  • Betumumab NoN putative USAN
  • Biciromab brallobarbital YesY INN
  • Bivatuzumab mertansine YesY rINN, multiple studies

[edit] C

  • Canakinumab YesY INN, one study
  • Cantuzumab mertansine YesY rINN, multiple studies
  • Capromab pendetide YesY in clinical use since 1996
  • Catumaxomab YesY rINN, in phase II/III studies
  • Cedelizumab YesY INN, but no studies
  • Cetforlimumab NoN
  • Cetinlimumab NoN
  • Cetlalimumab NoN
  • Cetolimumab NoN
  • Cidfusituzumab NoN
  • Cidtuzumab NoN
  • Citilimumab NoN
  • Clenoliximab YesY INN, multiple studies
  • Cynosumab NoN

[edit] D

  • Dacetuzumab YesY USAN of SG-40
  • Denosumab YesY rINN, multiple studies
  • Destilimumab NoN
  • Detumomab YesY INN
  • Doraglizumab NoN putative USAN
  • Dorlimomab aritox YesY INN
  • Dorlixizumab YesY suggested USAN
  • Dorlizumab NoN putative USAN
  • Drinalizumab NoN putative USAN
  • Duntumumab NoN putative USAN of zalutumumab
  • Durimulumab NoN putative USAN of stamulumab
  • Durlizumab NoN putative USAN
  • Durmulumab NoN putative USAN of stamulumab

[edit] E

  • Ecromeximab YesY rINN/USAN; 292819-64-8 ; nothing in PubMed
  • Edobacomab YesY multiple studies
  • Efalizumab YesY in clinical use
  • Efungumab YesY rINN, multiple studies, twice denied approval by EMEA
  • Elsilimomab YesY INN, in phase II trials
  • Epitumomab cituxetan YesY rINN, 263547-71-3
  • Epkizumab NoN
  • Epratuzumab YesY multiple studies
  • Erlizumab YesY rINN, 211323-03-4
  • Ertumaxomab YesY one published study, in phase II trials
  • Etaracizumab YesY suggested USAN, phase I trials completed
  • Exbivirumab YesY rINN, 569658-80-6 ; nothing in PubMed
  • Extumumab NoN putative USAN

[edit] F

  • Fanolesomab YesY in clinical use (diagnostic agent)
  • Faralimomab YesY INN
  • Felvizumab YesY INN
  • Fontolizumab YesY multiple studies; structure deposited in PDB
  • Futumumab NoN putative USAN

[edit] G

  • Galiximab YesY multiple studies, in phase III trials
  • Gantenerumab YesY rINN
  • Gavilimomab YesY rINN, two studies
  • Gemtuzumab ozogamicin YesY in clinical use
  • Genosumab NoN
  • Golimumab YesY multiple studies, in phase III trials
  • Gomiliximab YesY USAN

[edit] H

  • Hylizumab NoN putative USAN

[edit] I

  • Ibalizumab YesY one study
  • Igovomab YesY INN (diagnostic agent)
  • Imciromab YesY multiple studies, in clinical use
  • Inolimomab YesY multiple studies
  • Inotuzumab ozogamicin YesY multiple studies
  • Intumumab NoN putative USAN
  • Ipilimumab YesY rINN, multiple studies
  • Iratumumab YesY rINN/USAN

[edit] K

  • Keliximab YesY rINN, multiple studies

[edit] L

  • Labetuzumab YesY INN, multiple studies
  • Lebrilizumab YesY USAN under consideration
  • Lemalesomab YesY INN
  • Lerdelimumab YesY INN, multiple studies
  • Lexatumumab YesY INN, multiple studies
  • Libivirumab YesY INN
  • Lintuzumab YesY INN, multiple studies
  • Lucalizumab NoN
  • Lucatumumab YesY USAN
  • Lumiliximab YesY INN, multiple studies

[edit] M

  • Mapatumumab YesY INN, multiple studies
  • Maslimomab YesY INN
  • Matenazumab NoN purported USAN
  • Matuzumab YesY INN, in phase II trials
  • Mepolizumab YesY INN, multiple studies
  • Metelimumab YesY INN, in phase II trials
  • Minretumomab YesY INN
  • Mitumomab YesY INN, in phase III trials
  • Morolimumab YesY INN
  • Motavizumab YesY INN, multiple studies
  • Muromonab-CD3 YesY in clinical use

[edit] N

  • Nacolomab tafenatox YesY INN
  • Naptumomab estafenatox YesY INN
  • Nebacumab YesY INN, multiple studies
  • Nerelimomab YesY INN, one study in PubMed
  • Neutrospec YesY trade name of 99m-Tc fanolesomab
  • Nimotuzumab YesY INN, multiple studies
  • Nofetumomab merpentan YesY diagnostic agent, multiple studies
  • Nolovizumab NoN
  • Numavizumab NoN purported USAN

[edit] O

  • Ocrelizumab YesY INN, in phase III trials
  • Odulimomab YesY INN, multiple studies
  • Ofatumumab YesY rINN, phase I/II trial results published
  • Oregovomab YesY INN, multiple trials ongoing
  • Oteliximab NoN
  • Otelixizumab YesY USAN, news story

[edit] P

  • Pagibaximab YesY INN, PMID 17939955
  • Palivizumab YesY in clinical use
  • Pascolizumab YesY INN, two PubMed hits
  • Pecfusituzumab NoN
  • Pectuzumab NoN
  • Pemtumomab YesY multiple studies, in phase III trials
  • Pexelizumab YesY pINN, multiple studies
  • Pintumomab YesY move to INN (technetium (99mTc) pintumomab)
  • Priliximab YesY one study
  • Pritumumab YesY INN

[edit] Q

  • Quartuzumab NoN
  • Quetumumab NoN

[edit] R

  • Ralivizumab NoN
  • Raxibacumab YesY USAN, 565451-13-0
  • Regavirumab YesY INN, three reports in PubMed
  • Resatumumab NoN
  • Reslivizumab NoN purported USAN
  • Reslizumab YesY INN/USAN, multiple studies
  • Restumumab NoN purported USAN
  • Resyvizumab NoN purported USAN
  • Rilotumumab NoN
  • Rosutumumab NoN
  • Rovelizumab YesY INN, PMID 16100700
  • Ruplizumab YesY INN, PMID 15046525

[edit] S

  • Satumomab pendetide YesY diagnostic agent, in clinical use; INN is satumomab
  • Sevirumab YesY INN, multiple studies
  • Sibrotuzumab YesY INN, multiple studies
  • Siplizumab YesY INN, three PubMed hits
  • Sontuzumab YesY INN
  • Stamulumab YesY INN, two PubMed hits
  • Sulesomab YesY INN, in clinical use
  • Synosumab NoN

[edit] T

  • Tacatuzumab tetraxetan--in SciFinder CAS#476413-07-7
  • Tadocizumab--in SciFinder CAS#339086-80-5
  • Talineuzumab--not in PubMed or SciFinder
  • Talizumab--in PubMed
  • Taneuzumab--not in PubMed or SciFinder
  • Tanirazumab--not in PubMed or SciFinder
  • Taplitumomab paptox--in SciFinder CAS#235428-87-2
  • Tefibazumab--in PubMed
  • Teglizumab--not in PubMed or SciFinder
  • Telimomab aritox--in SciFinder CAS#117305-33-6
  • Teneliximab--in SciFinder CAS#299423-37-3
  • Teplizumab--in SciFinder CAS#876387-05-2
  • Tilolizumab--not in PubMed or SciFinder
  • Tiratumumab--not in PubMed or SciFinder
  • Tocilizumab--in PubMed
  • Tolizumab--not in PubMed or SciFinder
  • Toralizumab--in SciFinder CAS#252662-47-8
  • Tralizumab--not in PubMed or SciFinder
  • Treglizumab--not in PubMed or SciFinder
  • Trelizumab--not in PubMed or SciFinder
  • Tremelimumab--in PubMed
  • Trilizumab--not in PubMed or SciFinder
  • Tritumumab--not in PubMed or SciFinder
  • Trixatumumab--not in PubMed or SciFinder
  • Tucotuzumab celmoleukin--in PubMed
  • Tucusituzumab--not in PubMed or SciFinder
  • Tuvirumab--in PubMed

[edit] U

  • Ubrelizumab--not in PubMed or SciFinder
  • Umavizumab--not in PubMed or SciFinder
  • Urtoxazumab--in SciFinder CAS#502496-16-4

[edit] V

  • Valtumumab--not in PubMed or SciFinder
  • Vapaliximab--in SciFinder CAS # 336801-86-6
  • Vepalimomab--in PubMed
  • Vexatumumab--not in PubMed or SciFinder
  • Visilizumab--in PubMed
  • Votumumab--in SciFinder CAS#148189-70-2

[edit] X

  • Xalizumab--not in PubMed or SciFinder

[edit] Z

  • Zalutumumab--in SciFinder CAS#667901-13-5
  • Zanolimumab--in PubMed
  • Ziralimumab--not in PubMed or SciFinder
  • Zolimomab aritox--in PubMed
  • Zulizumab--not in PubMed or SciFinder